DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20204100

Prescription pattern in the management of chronic obstructive pulmonary disease patients in a tertiary hospital: an observational study

Poonam Salwan, Juhi Singla, Shalini Salwan

Abstract


Background: Drug utilization studies promote rational use of drugs and help to decrease the adverse drug reactions. Such studies are powerful tools to evaluate the role of drugs in the society. The present study is aimed to analyse and evaluate the trends and patterns of prescribing drugs among chronic obstructive pulmonary disease (COPD) patients.

Methods: A prospective observational study was conducted in 112 patients of COPD admitted in the general and pulmonary medicine departments over a period of 1-year in SGT Medical College, Hospital and Research Institute, SGT University, Gurugram. Patients, who satisfied the inclusion criteria, were enrolled in the study after taking informed consent. Data was collected by using the specially designed data entry form and put in tabulated form. The results were expressed as percentages. The following information was collected for each patient: social demographics, smoking history, prescribed COPD treatments. Health related quality of life indices were obtained using validated questionnaires.

Results: Out of the 112-study population, male patients were more in number (76.36%). The majority of the patients were from the age group of 61-70 years (47.2%) with 56.36% patients showing severe rating (poor score) of quality of life on COPD assessment test. Smoking was found to be more prominent in the study population (71.42%). Inhaled corticosteroids (67.85%) were most prescribed class of drugs in the management of COPD followed by systemic bronchodilators (64.28%). The most commonly prescribed bronchodilator was systemic methylxanthine (deriphylline-64.28%) followed by systemic β2 agonist (Terbutaline-62.5%). Inhaled corticosteroids (67.85%) were prescribed more often than systemic corticosteroids. Among antimicrobials, the most commonly prescribed drug was Amoxicillin-clavulanic combination (35.71%) and ceftriaxone (35.71%). Considering the drugs prescribed for co-morbid conditions, proton- pump inhibitors (73.21%) topped the list followed by antihistaminic (37.5%) for allergic conditions.

Conclusions: The study concludes that symptomatic treatment was given to COPD patients in the hospital. The prescribing pattern was found to be in concordance with the current global Initiative for chronic obstructive lung disease (GOLD) guidelines in the management of COPD patients.


Keywords


Bronchodilators, Drug utilization, Prescription pattern

Full Text:

PDF

References


Jindal SK, Aggarwal AN, Gupta D, Agarwal R. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (in search). Int J Tubercul Lung Disea. 2012;16:1270-7.

Reilly JJ. Chronic obstructive pulmonary disease (COPD). Harrisons Principles of Internal Medicine, McGraw-Hill, New York; 2012:2151-60.

Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lanc. 2007;370(9589):765-73.

Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006;367:1216-9.

Global initiative for chronic obstructive lung disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2014. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23. pdf. Accessed on 20th June 2019.

Vijayan VK. Chronic obstructive pulmonary disease. Indian J Med Res. 2013;137:251-69.

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. LoS Med. 2006;3:e442.

Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-73.

Burney P. The pharmacoepidemiology of COPD: Recent advances and methodological discussion. Europ J Respirat. 2003;22:1s-44s.

Rehman A, Hassali MA, Muhammad SA, Shakeel S, Chin OS, Ali IA, et al. Economic burden of chronic obstructive pulmonary disease patients in Malaysia: a longitudinal study. Pharmaco Economics-Open. 2020:1-0.

Drug utilization studies: methods and uses. Citation: Available at: https://apps.who.int/iris/ handle/10665/260517. Accessed on 12th May 2020.

Faheemuddin MD, Ramaiah B, Kiran SS, Kumari BS, Vijayalaxmi M. Evaluation of Medication Adherence in COPD Patients and their Drug Utilization Pattern. I Med Pub. 2016;3:1-9.

Mohan A, Premanand R, Reddy LN, Rao MH, Sharma SK, Kamity R, et al. Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. Bio Med Centr Pulm Med. 2006;6:27.

Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118:1278-85.

McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4):CD003900.

Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Coch Databa Syst Rev. 2003;2:CD002168.

Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochr Database Syst Rev. 2005;1:CD001288.

Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochr Databa Syst Rev. 2006;2:CD004403.

Veettil SK, Rajiah K, Kumar S. Study of drug utilization pattern for acute exacerbation of chronic obstructive pulmonary disease in patients attending a Government Hospital in Kerala, India. J Family Med Prim Care. 2014;3(3):250-4.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-54.

Miravitlles M, Murio C, Guerrero T, Gisbert R. DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449-55.